Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pfizer Inc"


25 mentions found


Vaccinated People Account for Half of New Covid-19 Delta Cases in Israeli Outbreak
  + stars: | 2021-06-25 | by ( Dov Lieber | ) www.wsj.com sentiment -0.99   time to read: +1 min
Preliminary findings by Israeli health officials suggest about 90% of the new infections were caused by the Delta variant, according to Ran Balicer, who leads an expert advisory panel on Covid-19 for the government. Around half of those infected were fully vaccinated, he said. Israel is now reassessing its Covid-19 regulations after moving to open up its society and economy after multiple lockdowns last year. “The entrance of the delta variant has changed the transition dynamics,” said Prof. Balicer, who is also the chief innovation officer for Israel’s largest health-management organization, Clalit. The Delta variant, which first emerged in India in late 2020 and is also known as B.1.617.2, has now been detected in more than 70 countries.
Persons: Ran Balicer, , Balicer Organizations: Pfizer Inc Locations: TEL AVIV, Israel, India, U.S
The estimate is included in a report, which is to be discussed on Thursday at a board meeting of Gavi, a vaccine alliance that co-leads the WHO's COVID-19 vaccine programme COVAX. read moreThe document shows that the WHO considers annual boosters for high-risk individuals as its "indicative" baseline scenario, and boosters every two years for the general population. The document, which is dated June 8 and is still "work in progress", also predicts under the base case that 12 billion COVID-19 vaccine doses will be produced globally next year. That could be compounded by the need for annual boosters for the entire world, and not just the most vulnerable, to combat variants and limited duration of protection. There would be no need for boosters as vaccines would show strong efficacy against variants and long protection.
Persons: Denis Balibouse, BioNTech, Gavi, Johnson, Francesco Guarascio, Josephine Mason, Emelia Organizations: World Health Organization, WHO, REUTERS, Reuters, Moderna Inc, Pfizer Inc, International Federation of Pharmaceutical Manufacturers & Associations, European Union, Pfizer, Moderna, AstraZeneca, Thomson Locations: Geneva, Switzerland, BRUSSELS
AstraZeneca vaccine effective against COVID-19 variants identified in India
  + stars: | 2021-06-22 | by ( ) www.reuters.com sentiment -0.99   time to read: +1 min
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado RuvicJune 22 (Reuters) - AstraZeneca Plc's (AZN.L) COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, the company said on Tuesday, citing a study. The study by the Oxford University investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralize the Delta and Kappa variants, the statement said. read moreThe latest Oxford study results are built on the recent analysis by PHE, the company said. The Delta variant is becoming the globally dominant version of the disease, the World Health Organization's chief scientist said on Friday.
Persons: Dado Ruvic, PHE, Aishwarya Nair, Arun Koyyur Organizations: Astra, AstraZeneca, REUTERS, Delta, Oxford University, Public Health, Pfizer Inc, Health Organization's, Thomson Locations: India, Oxford, Bengaluru
WASHINGTON—The White House on Monday detailed plans to allocate 55 million Covid-19 vaccine doses it is donating overseas, saying the shipments would likely take longer than President Biden’s initial target of sending them out by the end of June. White House officials said the delays were related to logistical challenges in countries set to receive the vaccines. Mr. Biden said last month that the administration expected to export 80 million donated doses by the end of June. In addition, the administration expected 60 million of the donated doses to come from the vaccine manufactured by AstraZeneca, pending a safety review, but it hasn’t received clearance from the Food and Drug Administration. Mr. Biden announced this month plans to donate 500 million coronavirus vaccine doses produced by Pfizer to the rest of the world.
Persons: WASHINGTON, Biden’s, hasn’t, Biden, Laura Kammermann, Jen Psaki, Johnson, Sabrina Siddiqui Organizations: White, AstraZeneca PLC, Covid, West Bank, AstraZeneca, Food and Drug Administration, Moderna Inc, Pfizer Inc, Johnson, Pfizer Locations: Covax, America, Asia, Africa, Colombia, Haiti, Afghanistan, Pakistan, Ukraine, Bosnia, Gaza, U.S, India, Brazil
Philippines seals deal for 40 mln Pfizer/BioNTech COVID-19 doses
  + stars: | 2021-06-20 | by ( ) www.reuters.com + 0.00   time to read: +3 min
Vials of the Pfizer-BioNTech vaccine are pictured in a vaccination centre in Geneva, Switzerland, February 3, 2021. Deliveries of the vaccine, among several brands of coronavirus shots allowed for emergency use in the Southeast Asian country, will begin in August, Carlito Galvez, head of the government's COVID-19 vaccine procurement, said on Sunday. With the latest deal, the Philippines has secured the delivery of 113 million doses from five vaccine manufacturers - also including China's Sinovac (SVA.O) with 26 million doses, Russia's Sputnik V with 10 million doses, 20 million doses from Moderna (MRNA.O) and 17 million doses from AstraZeneca. read moreThe Philippines also expects vaccine deliveries from the international COVAX facility to reach 44 million doses, while 16 million doses of vaccines developed by Novavax (NVAX.O) and Johnson & Johnson (JNJ.N) were still under negotiation, Galvez said. The Philippines will allow the Pfizer-BioNTech vaccine to be given to children aged 12 to 15, possibly starting later this year when the vaccine inventory will have increased and the inoculation of the priority sectors has been completed, he said.
Persons: Denis Balibouse, Carlito Galvez, China's, Johnson, Galvez, Enrico Dela Cruz, William Mallard Organizations: Pfizer, REUTERS, August, Philippine, Pfizer Inc, Sputnik, Moderna, AstraZeneca, Novavax, Thomson Locations: Geneva, Switzerland, August Philippines, MANILA, Philippines, Manila, COVID, Taiwan, United States
S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people
  + stars: | 2021-06-18 | by ( Sangmi Cha | ) www.reuters.com + 0.00   time to read: +2 min
A health worker gets a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a COVID-19 vaccination center in Seoul, South Korea, March 10, 2021. REUTERS/Kim Hong-JiSEOUL, June 18 (Reuters) - Some 760,000 South Koreans who have received a first dose of AstraZeneca Plc's (AZN.L) COVID-19 vaccine will be offered Pfizer Inc's (PFE.N) vaccine as a second shot due to shipment delays by global vaccine sharing scheme COVAX, the government said. Several countries, including Canada and Spain, have already approved such dose-mixing mainly due to concerns about rare and potentially fatal blood clots linked to the AstraZeneca vaccine. They are from AstraZeneca, Pfizer, Johnson & Johnson (JNJ.N) and Moderna (MRNA.O). South Korea said last month it will conduct a clinical trial that mixes COVID-19 doses from AstraZeneca with those from Pfizer and others.
Persons: Kim Hong, Ji, Pfizer Inc's, Johnson, Jeong Eun, kyeong, Sangmi Cha, Miyoung Kim, Raju Gopalakrishnan Organizations: Pfizer, REUTERS, AstraZeneca Plc's, AstraZeneca, South, Johnson, Moderna, Korea Disease Control, Prevention Agency, Thomson Locations: Seoul, South Korea, Ji SEOUL, Canada, Spain, Korea
CureVac Value Halves in Reminder of Vaccine Research Risks
  + stars: | 2021-06-17 | by ( Denise Roland | ) www.wsj.com sentiment -1.00   time to read: +1 min
CureVac NV’s market value nearly halved Thursday after the Nasdaq-listed German company reported disappointing results for its experimental Covid-19 vaccine, even as executives voiced hope that the jab could still find a use in certain groups. Investors wiped around $9 billion off CureVac’s value after the company said its vaccine was just 47% effective against the disease in an interim analysis of a large trial, one of the poorest results for any prospective Covid-19 shot. CureVac’s vaccine uses a gene-based technology called messenger RNA, similar to that used by Moderna Inc. and Pfizer Inc., with its partner BioNTech SE , to make Covid-19 vaccines. BioNTech, like CureVac a German company and a pioneer of mRNA research, shot to fame and saw its value soar after its own vaccine candidate showed high efficacy in late-stage trials last year and went on to become the first Covid-19 vaccine authorized in the U.S. and Europe. It developed that vaccine and produces and markets it together with Pfizer Inc. in the U.S. and Europe.
Persons: hadn’t, Organizations: Nasdaq, Investors, Moderna Inc, Pfizer Inc Locations: U.S, Europe
The United States has already begun shipping doses, said White House COVID-19 response coordinator Jeff Zients, adding that some shots will go to Canada on Thursday and some will go to Brazil in the coming weeks. Canada said it expects to receive around 1 million Moderna Inc (MRNA.O) shots from the United States on Thursday. The Biden administration earlier this month announced plans for how it will allocate 25 million shots and said it would allocate the remaining 55 million shots by the end of June. The United States has been increasing shot shipments abroad as it progresses quickly in its vaccination campaign for its own residents. The White House announced last week that it was purchasing 500 million Pfizer Inc (PFE.N) shots to donate to poorer countries in 2021 and 2022.
Persons: Dado, Jeff Zients, Biden, Zients, Rochelle Walensky, Carl O'Donnell, Chizu Organizations: Johnson, Pfizer, REUTERS, U.S, United, Moderna Inc, White House, Pfizer Inc, U.S . Centers for Disease Control, Prevention, Thomson Locations: United States, Canada, Brazil, U.S, India
CureVac Covid-19 Vaccine Candidate Disappoints in Key Study
  + stars: | 2021-06-16 | by ( Peter Loftus | ) www.wsj.com sentiment -0.94   time to read: +1 min
CureVac NV said Wednesday its experimental Covid-19 vaccine was 47% effective against the disease in an interim analysis of a large clinical trial, a disappointing outcome likely to dim the shot’s prospects for wider use. CureVac’s vaccine uses a gene-based technology, messenger RNA, similar to the technology used by Moderna Inc. and Pfizer Inc., with its partner BioNTech SE , to make Covid-19 vaccines. In comparison, those vaccines were at least 94% effective in large clinical trials last year before new virus variants spread significantly. The Moderna and Pfizer shots have formed the backbone of mass vaccination campaigns in the U.S. and other countries. CureVac’s vaccine is slightly different than the Pfizer and Moderna shots, with a formulation that allows it to be stored at higher temperatures than the other shots.
Persons: CureVac Organizations: CureVac NV, European Commission, GlaxoSmithKline PLC, Novartis AG, Moderna Inc, Pfizer Inc, Moderna, Pfizer Locations: Europe, U.S
Pfizer's rheumatoid arthritis drug shows benefit in COVID-19 pneumonia
  + stars: | 2021-06-16 | by ( ) www.reuters.com sentiment -0.99   time to read: +1 min
REUTERS/Brian SnyderJune 16 (Reuters) - Pfizer Inc (PFE.N) said on Wednesday its oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study's main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published in the New England Journal of Medicine. Pfizer said the incidence of death or respiratory failure was 18.1% for patients treated with the drug compared to 29% for placebo. Serious adverse events occurred in 20 patients treated with the drug compared to 17 patients on placebo. Pfizer and German partner BioNTech SE's vaccine is one of the three vaccines currently approved for emergency use in the United States.
Persons: Brian Snyder, COVID, BioNTech, Amruta Khandekar, Arun Koyyur Organizations: Pfizer, REUTERS, Pfizer Inc, New England, of Medicine, Thomson Locations: Cambridge , Massachusetts, U.S, Brazil, United States
International Olympic Committee (IOC) Vice President and Tokyo 2020 Olympic Games Coordination Commission Chairman John Coates arrives at Haneda Airport in Tokyo, Japan June 15, 2021. REUTERS/Issei KatoOlympics organisers prepared on Tuesday to unveil their latest "playbook" of rules to control COVID-19 infections as Japan's government pondered whether to extend a state of emergency and senior Olympics official John Coates arrived in Tokyo. Organisers' rules already mandate wearing masks by athletes and others in most situations and frequent testing for COVID-19. Just under one-third wanted the Games cancelled while 61% wanted either a cap on spectators or no spectators at all. Organisers have already decided against allowing spectators from abroad and will make a call on domestic spectators later this month.
Persons: John Coates, Issei Kato, Yasutoshi Nishimura, Japan's, Tamayo Marukawa, Yoshihide Suga, Jeff Shell, Moon Jae, Suga Organizations: Olympic Committee, REUTERS, Olympics, International Olympic Committee, Games, Pfizer Inc, Kyodo, IOC, NHK, Comcast Corp, Yomiuri, South, Thomson Locations: Tokyo, Japan, Tokyo . Coates, Seoul, South Korea
Brazil's Bolsonaro asks Pfizer to speed up COVID vaccine delivery
  + stars: | 2021-06-15 | by ( ) www.reuters.com sentiment -0.92   time to read: +2 min
Brazil's President Jair Bolsonaro reacts during a ceremony of signing the Vaccine Technology Transfer Agreement for Oxford/AstraZeneca coronavirus disease (COVID-19) vaccines, in Brasilia, Brazil, June 1, 2021. REUTERS/Ueslei MarcelinoBrazilian President Jair Bolsonaro on Monday asked Pfizer Inc (PFE.N) to bring forward planned delivery of COVID-19 vaccines, a government source said, aiming to speed up a slow national inoculation program. The commission heard testimony that the government never replied to letters from Pfizer last year offering to sell vaccines. read moreBrazil signed a deal with Pfizer in March to purchase 100 million doses, and the first doses arrived in late April. A second contract in May provided for another 100 million doses to be delivered in the fourth quarter.
Persons: Jair Bolsonaro, Ueslei Marcelino, Bolsonaro, Marta Diez, Carlos Murillo Organizations: Oxford, AstraZeneca, REUTERS, Monday, Pfizer Inc, Pfizer, Pfizer Brasil, Reuters, China's Sinovac Biotech, AstraZeneca Plc, Thomson Locations: Brasilia, Brazil, COVID
Novavax Covid-19 Vaccine Is 90% Effective in Key Study
  + stars: | 2021-06-14 | by ( Peter Loftus | ) www.wsj.com + 0.00   time to read: +10 min
Despite the study results, Novavax said it needs much of that time to ensure that its manufacturing processes meet regulatory standards. Novavax started its late-stage, or Phase 3, trial of the Covid-19 vaccine in late December. Novavax said that the vaccine was 93.2% effective combined against the variants of concern and variants of interest in the study. One challenge conducting the study, Novavax said, was the availability of authorized vaccines. In all, about 5,000 people dropped out of the study, Novavax said, meaning the Covid-19 cases that were used to determine efficacy occurred among the remaining 25,000 study subjects, Dr. Glenn said.
Persons: Novavax, , Gregory Glenn, T.J, Kirkpatrick, Stanley Erck, Erck, Biden, Johnson, wasn’t, Glenn, Peter Loftus Organizations: Novavax Inc, Wall, Health, U.S . Food, Drug Administration, Pfizer Inc, Moderna Inc, Pfizer, BioNTech, Moderna, FDA, D.C, GlaxoSmithKline, Johnson, AstraZeneca, National Institutes of Health, peter.loftus Locations: U.S, Mexico, Gaithersburg, Md, China, Covid, Washington, Chile, Brazil, India
Public health officials in the U.K. say they are increasingly confident that vaccines offer significant protection against the Delta variant of coronavirus, a hopeful sign as the highly transmissible strain spreads across the world. Separate studies from researchers in England and Scotland published Monday found that while protection against infection was somewhat diminished against Delta compared with more established variants, two doses of vaccine offered considerable protection against severe illness and hospitalization. The findings are the latest indicating that Covid-19 vaccines are able to protect people against new variants, despite early concerns that the variants might be able to elude them. An analysis of more than 14,000 Delta cases by England’s public health agency found a double dose of the shot developed by Pfizer Inc. and BioNTech SE reduces the risk of hospitalization after infection with Delta by 96%. Two doses of the vaccine developed by the University of Oxford and AstraZeneca reduces the risk by 92%, Public Health England said.
Persons: , Aziz Sheikh Organizations: Delta, University of Edinburgh’s, Institute of, Pfizer Inc, University of Oxford, AstraZeneca, Public Health Locations: England
U.S. has administered over 309 million doses of Covid-19 vaccines, CDC says
  + stars: | 2021-06-13 | by ( ) www.nbcnews.com sentiment -0.99   time to read: 1 min
The United States had administered 309,322,545 doses of Covid-19 vaccines and distributed 374,398,105 doses in the country as of Sunday morning, the U.S. Centers for Disease Control and Prevention said. Those figures were up from the 308,112,728 doses of vaccine that the CDC said had been administered as of Saturday, out of 374,397,205 doses delivered. The agency said 173,840,483 people in the United States had received at least one dose of a vaccine, while 143,921,222 people were fully vaccinated as of 6 a.m. ET on Sunday. The CDC tally includes the two-dose vaccines from Moderna Inc and Pfizer Inc/BioNTech/ as well as Johnson & Johnson's one-shot vaccine.
Persons: Johnson Organizations: U.S . Centers for Disease Control, Prevention, CDC, United States, Moderna Inc, Pfizer Inc Locations: States, United
Can Schools Mandate Covid-19 Vaccines for Children? What We Know
  + stars: | 2021-06-11 | by ( Yoree Koh | ) www.wsj.com sentiment -0.98   time to read: +1 min
Many education officials, public-health officials and parents believe that vaccinating children against Covid-19 will play a key role in resuming normal life in time for in-person learning in the fall. That stance has led some parents to wonder: Will K-12 students be mandated to receive the vaccine to be allowed on campus this fall? Children as young as 12 years old are now eligible to receive the Covid-19 vaccine from Pfizer Inc. and BioNTech SE . About 53% of parents of children between the ages of 12 and 15 said they plan to have their child vaccinated. The same percentage of parents of children under 12 said they planned to have their children vaccinated once the green light is given.
Persons: K Organizations: Covid, Pfizer Inc, Moderna Inc, Pfizer, U.S . Centers for Disease Control
(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.) (Updates to market close)June 10 (Reuters) - Wall Street stocks ended firmer on Thursday, with the S&P 500 hitting a record closing high, as economic data appeared to support the Federal Reserve’s assertion that the current wave of heightened inflation will be temporary. All three major U.S. stock indexes advanced, with market-leading megacap stocks putting the Nasdaq out front. Unofficially, the Dow Jones Industrial Average rose 12.21 points, or 0.04%, to 34,459.35, the S&P 500 gained 19.71 points, or 0.47%, to 4,239.26 and the Nasdaq Composite added 106.86 points, or 0.77%, to 14,018.61. Among the 11 major sectors of the S&P 500, healthcare enjoyed the largest percentage gains.
Persons: smallcaps, , Ryan Detrick, Detrick, Joe Biden’s, Stephen Culp, Ambar Warrick, Richard Chang Organizations: Nasdaq, Labor, Financial, U.S . House, Dow Jones, Treasury, GameStop Corp, Clover Health Investments Corp, AMC Entertainment Holdings, Beyond Inc, GEO Group, Boeing, Reuters, United Airlines, Airbus, Pfizer Inc Locations: Charlotte , North Carolina, United
S&P 500 headed for record high as inflation seems temporary
  + stars: | 2021-06-10 | by ( Stephen Culp | ) www.reuters.com + 0.00   time to read: +3 min
(Reuters) - Wall Street stocks rose on Thursday, with the S&P 500 on course to hit an all-time closing high, as the much-anticipated consumer price index report signaled that the current inflation wave will be transitory. REUTERS/Brendan McDermidAll three major U.S. stock indexes were higher, with market-leading megacap stocks putting the Nasdaq out front. The Dow Jones Industrial Average rose 126.15 points, or 0.37%, to 34,573.29; the S&P 500 gained 25.09 points, or 0.59%, at 4,244.64; and the Nasdaq Composite added 108.76 points, or 0.78%, at 14,020.51. Among the 11 major sectors of the S&P 500, healthcare enjoyed the largest percentage gains. The S&P 500 posted 57 new 52-week highs and no new lows; the Nasdaq Composite recorded 92 new highs and 11 new lows.
Persons: Brendan McDermid, , Colin Asher, ” Asher, Joe Biden’s, decliners Organizations: Reuters, New York Stock Exchange, REUTERS, Nasdaq, Labor, Mizuho, U.S . House, Dow Jones, Treasury, GameStop Corp, Clover Health Investments Corp, AMC Entertainment Holdings, Beyond Inc, GEO Group, Boeing Co, United Airlines, Boeing, Airbus, Pfizer Inc, NYSE Locations: St, New York City, U.S, London, United
Moderna’s Covid-19 Vaccine Seeks FDA Authorization for Use in Adolescents
  + stars: | 2021-06-10 | by ( Peter Loftus | ) www.wsj.com sentiment -0.99   time to read: +1 min
Moderna Inc. said Thursday it has asked U.S. health regulators to authorize the use of its Covid-19 shot in adolescents ages 12 to 17, setting up the potential availability of a second vaccine option for adolescents. The application means Moderna’s vaccine could be cleared for use in the older children this summer. Moderna is seeking authorization from the U.S. Food and Drug Administration after releasing results of a study in May showing that the vaccine safely induced immune response in adolescents and appeared to be protective against Covid-19 disease. “We are encouraged that the Moderna Covid-19 vaccine was highly effective at preventing Covid-19 and SARS-CoV-2 infection in adolescents,” Moderna Chief Executive Stephane Bancel said. The FDA could make a decision on Moderna’s request by early July if it follows the same kind of timetable if took with the Covid-19 vaccine from Pfizer Inc. and BioNTech SE .
Persons: Stephane Bancel Organizations: Inc, U.S . Food, Drug, Moderna, ” Moderna, FDA, Pfizer Inc Locations: Moderna, U.S, Covid
India has not granted indemnity to any COVID-19 vaccine maker, but the sources, who requested anonymity, said the government was having a change of heart. The government has already met one of Pfizer's other key demands by dropping a requirement that foreign vaccines undergo local trials. One of the sources said India was negotiating prices of $10-$12 per dose for foreign shots. The European Union is paying 15.5 euros ($18.86) per dose for the Pfizer vaccine developed with Germany's BioNTech (22UAy.DE). read moreThe Pfizer spokeswoman said the company had offered doses to many countries at a not-for-profit price.
Persons: Edgar Su, Johnson, Germany's Organizations: Pfizer, REUTERS, Pfizer Inc, Reuters, European, AstraZeneca, Thomson Locations: Singapore, India, China, United States
S&P 500 closes at record high as long-term inflation fears abate
  + stars: | 2021-06-10 | by ( Stephen Culp | ) www.reuters.com + 0.00   time to read: +3 min
People are seen on Wall St. outside the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2021. REUTERS/Brendan McDermidWall Street stocks ended firmer on Thursday, with the S&P 500 (.SPX) hitting a record closing high, as economic data appeared to support the Federal Reserve's assertion that the current wave of heightened inflation will be temporary. All three major U.S. stock indexes advanced, with market-leading megacap stocks putting the Nasdaq (.IXIC) out front. Unofficially, the Dow Jones Industrial Average (.DJI) rose 12.21 points, or 0.04%, to 34,459.35, the S&P 500 (.SPX) gained 19.71 points, or 0.47%, to 4,239.26 and the Nasdaq Composite (.IXIC) added 106.86 points, or 0.77%, to 14,018.61. Among the 11 major sectors of the S&P 500, healthcare (.SPXHC) enjoyed the largest percentage gains.
Persons: Brendan McDermid, Ryan Detrick, Detrick, Joe Biden's Organizations: New York Stock Exchange, REUTERS, Nasdaq, Labor, Financial, U.S . House, Dow Jones, Treasury, GameStop Corp, Clover Health Investments Corp, AMC Entertainment Holdings, Beyond Inc, GEO, Boeing Co, Reuters, United Airlines, Boeing, Airbus, Pfizer Inc, Thomson Locations: St, New York City, U.S, Charlotte , North Carolina, United
J&J CEO Says Covid-19 Vaccine Will Be Important Tool to Contain Pandemic
  + stars: | 2021-06-09 | by ( Peter Loftus | ) www.wsj.com sentiment -1.00   time to read: +1 min
Johnson & Johnson ’s chief executive said the company’s Covid-19 vaccine could still play a role in containing the global coronavirus pandemic despite its setbacks with production problems and safety concerns. J&J CEO Alex Gorksy said the company’s vaccine could be particularly useful outside the U.S. in developing countries. It is given in one dose and has more convenient storage requirements than some other vaccines. “We still believe that this is going to be a very important tool in the overall armamentarium to help overall contain Covid and make a big difference for the world,” Mr. Gorsky said Wednesday during a WSJ Tech Health Event. Millions of doses are at risk of expiring unused this month, partly due to canceled appointments during the pause.
Persons: Johnson, Johnson ’, Alex Gorksy, Mr, Gorsky Organizations: Pfizer Inc, Moderna Inc Locations: U.S
Wall Street reverses, closing lower ahead of inflation report
  + stars: | 2021-06-09 | by ( Stephen Culp | ) www.reuters.com + 0.00   time to read: +4 min
NEW YORK (Reuters) - Wall Street stocks ended lower on Wednesday, reversing earlier gains as institutional investors awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy. FILE PHOTO: A Wall Street sign is pictured outside the New York Stock Exchange in the Manhattan borough of New York City, New York, U.S., April 16, 2021. REUTERS/Carlo Allegri/File PhotoThe retail “meme stock” craze continued unabated. However, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath & Beyond reversed course to close lower. “It feels like alternative stock market,” Carlson added.
Persons: Carlo Allegri, , Chuck Carlson, , ” Carlson, Joe Biden, Shelley Capito, Campbell Soup, Biden, Drugmaker Organizations: YORK, U.S . Federal, New York Stock Exchange, REUTERS, Horizon Investment, Aethlon, GEO Group, Wrestling Entertainment, Clover Health, AMC Entertainment, Vanda Research, GameStop Corp, GameStop, Dow, Washington, Representatives, Philadelphia, Labor, Dow Jones, Nasdaq, Treasury, Pfizer Inc, Washington Post, Drugmaker Merck, Co Locations: Manhattan, New York City , New York, U.S, Hammond , Indiana, States
UPS shares fall as firm gets more selective on deliveries
  + stars: | 2021-06-09 | by ( ) www.reuters.com sentiment -1.00   time to read: +1 min
Snow falls at the United Parcel Service (UPS) WorldPort hub located at Louisville Muhammad Ali International Airport in Louisville, Kentucky, U.S., February 15, 2021. REUTERS/Bryan WoolstonUnited Parcel Service Inc (UPS.N)shares fell 6% on Wednesday as the company known for delivering everything from Amazon.com packages to coronavirus vaccines laid out plans to prioritize lucrative deliveries over volume. Shares in UPS, which have nearly doubled in value over the last year, dropped $12.62 to $197.14 in midday trading. Atlanta-based UPS forecast full-year revenue between $98 billion to $102 billion for 2023, compared with the average analyst estimate of $100.19 billion, according to Refinitiv data. UPS now plans to be carbon-neutral across its global operations by 2050.
Persons: Snow, Louisville Muhammad, Bryan Woolston, Carol Tome, Tome Organizations: United Parcel Service, Louisville Muhammad Ali International Airport, REUTERS, Bryan Woolston United Parcel Service Inc, UPS, Pfizer Inc, Thomson Locations: Louisville, Louisville , Kentucky, U.S, Atlanta
UPS shares fall as investors fret over post-pandemic growth plan
  + stars: | 2021-06-09 | by ( ) www.reuters.com sentiment -1.00   time to read: +2 min
Snow falls at the United Parcel Service (UPS) WorldPort hub located at Louisville Muhammad Ali International Airport in Louisville, Kentucky, U.S., February 15, 2021. REUTERS/Bryan WoolstonUnited Parcel Service Inc (UPS.N) shares fell as much as 6% on Wednesday as the company known for delivering everything from Amazon.com packages to coronavirus vaccines laid out plans for post-pandemic growth. About half of the margin expansion in the company's core U.S. market would be generated this year via price increases and increased business from SMBs, executives said. Healthcare deliveries, including temperature-monitored shipments from companies like vaccine maker Pfizer Inc (PFE.N), are among the most profitable in the business. Executives said its weekend delivery push uses existing infrastructure and that they are "looking" in to a same-day delivery service.
Persons: Snow, Louisville Muhammad, Bryan Woolston, Carol Tome Organizations: United Parcel Service, Louisville Muhammad Ali International Airport, REUTERS, Bryan Woolston United Parcel Service Inc, Wall, UPS, Amazon.com Inc, Pfizer Inc, Thomson Locations: Louisville, Louisville , Kentucky, U.S, Atlanta, United States, SMBs
Total: 25